Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: Value of non-modelled parameters.

O'Flynn EA, Collins D, D'Arcy J, Schmidt M, de Souza NM.

Eur J Radiol. 2016 Apr;85(4):837-42. doi: 10.1016/j.ejrad.2016.02.006. Epub 2016 Feb 5.

2.

Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.

Cho N, Im SA, Park IA, Lee KH, Li M, Han W, Noh DY, Moon WK.

Radiology. 2014 Aug;272(2):385-96. doi: 10.1148/radiol.14131332. Epub 2014 Apr 13.

PMID:
24738612
3.

Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.

Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE.

Invest Radiol. 2015 Apr;50(4):195-204. doi: 10.1097/RLI.0000000000000100.

4.

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.

Marinovich ML, Sardanelli F, Ciatto S, Mamounas E, Brennan M, Macaskill P, Irwig L, von Minckwitz G, Houssami N.

Breast. 2012 Oct;21(5):669-77. doi: 10.1016/j.breast.2012.07.006. Epub 2012 Aug 3. Review.

PMID:
22863284
5.

[Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].

Sun B, Song ST, Jiang ZF, Wang T, Zhang SH, Meng XY, Li XB, Yu CZ, Wu SK.

Zhonghua Zhong Liu Za Zhi. 2013 Jan;35(1):38-42. doi: 10.3760/cma.j.issn.0253-3766.2013.01.008. Chinese.

PMID:
23648298
6.

Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.

Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, Regge D, Aglietta M.

Breast Cancer Res Treat. 2004 Jan;83(1):67-76.

PMID:
14997056
7.

Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.

Minarikova L, Bogner W, Pinker K, Valkovič L, Zaric O, Bago-Horvath Z, Bartsch R, Helbich TH, Trattnig S, Gruber S.

Eur Radiol. 2017 May;27(5):1901-1911. doi: 10.1007/s00330-016-4565-2. Epub 2016 Sep 20.

8.

Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.

Fatayer H, Sharma N, Manuel D, Kim B, Keding A, Perren T, Velikova G, Lansdown M, Shaaban AM, Dall B.

Eur J Surg Oncol. 2016 Jul;42(7):965-72. doi: 10.1016/j.ejso.2016.03.019. Epub 2016 Apr 20.

9.

Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.

Shin HJ, Baek HM, Ahn JH, Baek S, Kim H, Cha JH, Kim HH.

NMR Biomed. 2012 Dec;25(12):1349-59. doi: 10.1002/nbm.2807. Epub 2012 May 6.

PMID:
22566277
10.

Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.

Henderson SA, Muhammad Gowdh N, Purdie CA, Jordan LB, Evans A, Brunton T, Thompson AM, Vinnicombe S.

Br J Radiol. 2018 Jul;91(1087):20180123. doi: 10.1259/bjr.20180123. Epub 2018 May 2.

PMID:
29641224
11.

Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.

Li SP, Makris A, Beresford MJ, Taylor NJ, Ah-See ML, Stirling JJ, d'Arcy JA, Collins DJ, Kozarski R, Padhani AR.

Radiology. 2011 Jul;260(1):68-78. doi: 10.1148/radiol.11102493. Epub 2011 Apr 18.

PMID:
21502383
12.

Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.

Bufi E, Belli P, Costantini M, Cipriani A, Di Matteo M, Bonatesta A, Franceschini G, Terribile D, Mulé A, Nardone L, Bonomo L.

Clin Breast Cancer. 2015 Oct;15(5):370-80. doi: 10.1016/j.clbc.2015.02.002. Epub 2015 Feb 21.

PMID:
25891905
13.

Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.

Abramson RG, Li X, Hoyt TL, Su PF, Arlinghaus LR, Wilson KJ, Abramson VG, Chakravarthy AB, Yankeelov TE.

Magn Reson Imaging. 2013 Nov;31(9):1457-64. doi: 10.1016/j.mri.2013.07.002. Epub 2013 Aug 15.

14.

Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.

Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, d'Arcy JA, Collins DJ, Padhani AR.

Radiology. 2010 Dec;257(3):643-52. doi: 10.1148/radiol.10100421. Epub 2010 Sep 21.

PMID:
20858850
15.

Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.

Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA.

Radiology. 2012 Apr;263(1):53-63. doi: 10.1148/radiol.12111177.

PMID:
22438441
16.

Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.

Charehbili A, Wasser MN, Smit VT, Putter H, van Leeuwen-Stok AE, Meershoek-Klein Kranenbarg WM, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR.

Eur J Surg Oncol. 2014 Oct;40(10):1216-21. doi: 10.1016/j.ejso.2014.07.036. Epub 2014 Aug 8.

PMID:
25150151
18.

pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.

Reinisch M, Huober J, von Minckwitz G, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Schneeweiss A, Rhiem K, Lederer B, Untch M, Nekljudova V V, Loibl S.

Breast. 2017 Apr;32:73-78. doi: 10.1016/j.breast.2016.12.020. Epub 2017 Jan 5.

PMID:
28063331
19.

Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: are signal intensity-time curves adequate?

Woolf DK, Padhani AR, Taylor NJ, Gogbashian A, Li SP, Beresford MJ, Ah-See ML, Stirling J, Collins DJ, Makris A.

Breast Cancer Res Treat. 2014 Sep;147(2):335-43. doi: 10.1007/s10549-014-3072-x. Epub 2014 Aug 17.

PMID:
25129341
20.

MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer.

Bufi E, Belli P, Costantini M, Rinaldi P, Di Matteo M, Bonatesta A, De Santis MC, Nardone L, Terribile D, Mulé A, Bonomo L.

Br J Radiol. 2012 Nov;85(1019):e995-1103. doi: 10.1259/bjr/31819475. Epub 2012 Jul 4.

Supplemental Content

Support Center